Wellington Shields Capital Management LLC Sells 4,100 Shares of Edwards Lifesciences Co. (NYSE:EW)

Wellington Shields Capital Management LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 6.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 63,732 shares of the medical research company’s stock after selling 4,100 shares during the quarter. Wellington Shields Capital Management LLC’s holdings in Edwards Lifesciences were worth $4,718,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Versor Investments LP increased its holdings in Edwards Lifesciences by 102.5% in the 3rd quarter. Versor Investments LP now owns 4,455 shares of the medical research company’s stock valued at $294,000 after buying an additional 2,255 shares during the period. GSA Capital Partners LLP acquired a new position in Edwards Lifesciences in the third quarter worth about $481,000. MQS Management LLC bought a new position in Edwards Lifesciences during the third quarter worth about $245,000. Oppenheimer & Co. Inc. lifted its position in shares of Edwards Lifesciences by 3.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company’s stock worth $2,520,000 after buying an additional 1,441 shares during the period. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund boosted its stake in shares of Edwards Lifesciences by 422.3% in the 3rd quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 450,233 shares of the medical research company’s stock valued at $29,711,000 after purchasing an additional 364,030 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This represents a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 53,803 shares of company stock worth $3,900,976 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on EW shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Truist Financial reissued a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. The Goldman Sachs Group raised their target price on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Barclays lifted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Finally, Morgan Stanley increased their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $67.92 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $39.93 billion, a P/E ratio of 9.74, a PEG ratio of 4.82 and a beta of 1.12. The business has a 50-day moving average of $71.83 and a 200-day moving average of $70.32. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.